Hydramine and Infusion site cellulitis - a phase IV clinical study of FDA data

Summary:

Infusion site cellulitis is reported as a side effect among people who take Hydramine (diphenhydramine hydrochloride), especially for people who are female, 20-29 old, also take Prednisone, and have Eczema.

The phase IV clinical study analyzes which people have Infusion site cellulitis when taking Hydramine. It is created by eHealthMe based on reports of 113,450 people who have side effects when taking Hydramine from the FDA, and is updated regularly.

What is Hydramine?

Hydramine has active ingredients of diphenhydramine hydrochloride. It is often used in insomnia. eHealthMe is studying from 114,900 Hydramine users. Check the latest studies of Hydramine.

What is Infusion site cellulitis?

Infusion site cellulitis is found to be associated with 61 drugs and 137 conditions by eHealthMe. Check the latest studies of Infusion site cellulitis.

On Jul, 11, 2026

113,450 people reported to have side effects when taking Hydramine.
Among them, 18 people (0.02%) have Infusion site cellulitis.

Could Hydramine cause Infusion site cellulitis?

Among these 18 people:

What is the gender of people who have Infusion site cellulitis when taking Hydramine? *

female: 100 %
male: 0.0 %

What is the age of people who have Infusion site cellulitis when taking Hydramine? *

What are other drugs people take besides Hydramine? *

What are other side effects people have besides Infusion site cellulitis? *

Cataract (clouding of the lens inside the eye): 7 people, 38.89%
Sinusitis (inflammation of sinus): 7 people, 38.89%
Neuropathy Peripheral (surface nerve damage): 7 people, 38.89%
Bacteraemia (presence of bacteria in the blood): 7 people, 38.89%
Fever: 6 people, 33.33%
Pneumonia Streptococcal (pneumonia, caused by streptococcus pneumoniae): 5 people, 27.78%
Heart Rate Increased: 5 people, 27.78%
Infection: 5 people, 27.78%
Hypotension (abnormally low blood pressure): 5 people, 27.78%
Respiratory Tract Infection: 5 people, 27.78%

What are the existing conditions these people have? *

Immune System Disorder: 5 people, 27.78%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 5 people, 27.78%
Type 1 Diabetes: 4 people, 22.22%
Drug Hypersensitivity: 4 people, 22.22%
Immunodeficiency Common Variable: 3 people, 16.67%
Anaphylaxis (serious allergic reaction that is rapid in onset and may cause death): 2 people, 11.11%
Primary Immunodeficiency Syndrome: 2 people, 11.11%
Type Iv Hypersensitivity Reaction (delayed type hypersensitivity as the reaction takes two to three days to develop): 2 people, 11.11%
Ventricular Tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart): 1 person, 5.56%
Flatulence (flatus expelled through the anus): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Hydramine and have Infusion site cellulitis?

- Check whether Infusion site cellulitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Hydramine:

Hydramine (114,900 reports)

Browse all side effects of Hydramine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site cellulitis:

Infusion site cellulitis (61 drugs)

Browse all the conditions that are associated with Infusion site cellulitis:

Infusion site cellulitis (137 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on diphenhydramine hydrochloride (the active ingredients of Hydramine) and Hydramine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.